Fabhalta Alternatives Compared
| Fabhalta (iptacopan) | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
|---|
| Fabhalta (iptacopan) | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for C3 Glomerulopathy, Immunoglobulin A Nephropathy, Paroxysmal Nocturnal Hemoglobinuria. Fabhalta may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Hemolytic Uremic Syndrome, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Paroxysmal Nocturnal Hemoglobinuria. Empaveli may also be used for purposes not listed in this medication guide. |
Related suggestions Paroxysmal Nocturnal Hemoglobinuria
|
|||||||||||||||||||||||
| More about Fabhalta (iptacopan) | More about Ultomiris (ravulizumab) | More about Empaveli (pegcetacoplan) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Ultomiris has an average rating of 9.6 out of 10 from a total of 7 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Fabhalta side effects |
View all Ultomiris side effects |
View all Empaveli side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Fabhalta prices |
View all Ultomiris prices |
View all Empaveli prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
25 hours |
1192.8 hours |
192 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 337 drugs are known to interact with Fabhalta:
|
A total of 87 drugs are known to interact with Ultomiris:
|
A total of 80 drugs are known to interact with Empaveli:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 05, 2023 |
December 21, 2018 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Filspari
Filspari is used for primary immunoglobulin A nephropathy (IgAN), to slow kidney function decline ...
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Pulmicort Turbuhaler
Pulmicort (budesonide) is used to prevent asthma attacks. Includes Pulmicort side effects ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Eohilia
Eohilia (budesonide) suspension is used to treat eosinophilic esophagitis (EoE), to reduce symptoms ...
Vanrafia
Vanrafia (atrasentan) is a once-a-day non-steroidal tablet used for immunoglobulin A nephropathy ...
Entocort EC
Entocort EC is used to treat active, mild to moderate Crohn's disease (CD) that involves the ileum ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.